Each row is an authorised trial looking for participants. The plain-language title is written by our editorial team, and underneath it you can see the original registry title — so you can check for yourself that we did not change the meaning. We cannot tell you whether you are eligible, and we do not publish the hospital name: the international registry does not carry it, and a wrong name would send you to a room where nobody expects you. For the centre and the team's contact details, open the official record.
Trials recruiting now
Every title below has been rewritten in plain language by our editorial team, with the original underneath.
Trials testing a treatment · one study
Something new is being tried here: a medicine, a regimen or a procedure. If you join, you receive either the treatment under study or the standard one, and the team follows you closely.
Metastatic urothelial cancer after immunotherapy: a new medicine compared with platinum-based chemotherapy
A Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer with Disease Progression on or After Immunotherapy
For: Urothelial Cancer
3 centres: Institutul Oncologic Cluj, Cluj-Napoca · Centrul de Oncologie "Sfântul Nectarie", Craiova · Institutul Regional de Oncologie, Iași
Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy
Source: ClinicalTrials.gov, the public registry of the US National Library of Medicine. Data retrieved on 15 Sept 2026.
Worth reading before you talk to your doctor
Material from our library to help you prepare your questions.
The counts come from ClinicalTrials.gov and reflect trials marked in the registry as recruiting, with at least one site in Romania. A “recruiting” status does not guarantee that a site is still accepting patients on the day you check, because the registry may lag behind the situation at the hospital. For any decision, consult the official record and discuss it with your doctor.
Tell us what we can improve
We use optional technologies to measure usage and campaigns and improve OncoDots. You can accept, decline, or choose separately.